Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers

Figure 1 Study design. After ESD, all patients were administered an intravenous infusion of lansoprazole (20 mg; Takepron; Takeda Pharmaceutical, Osaka, Japan) every 12 h for 2 d, and received oral lansoprazole (30 mg/d) for 5 d. On postoperative day 7, the patients were randomly assigned to 2 groups and received either lansoprazole at a dose of 30 mg/d orally (PPI group; n = 45), or rebamipide (Mucosta; Otsuka Pharmaceutical Co., Tokyo, Japan) at a dose of 300 mg orally, 3 times a day (n = 45) for 8 wk. ESD: Endoscopic submucosal dissection; PPIs: Proton-pump inhibitors; div.: Drip intravenous infusion; POD: Postoperative days.

Figure 2 Flow chart of study participants. ESD: Endoscopic submucosal dissection.

Figure 3 Rates of healing in both groups. A: The rates of healing to S stage in both groups; B: The rates of healing to S stage in both groups according to resected location. L: Low stomach, M: Middle stomach; U: Upper stomach. C: The rates of healing to S stage in both groups. ¹Helicobacter pylori (H. pylori) positive ²H. pylori negative. D: The rates of healing to S stage in both groups in atrophic gastritis. ³Closed type; ⁴Open type. RM: Rebamipide.

Figure 4 Reduction ratio of the endoscopic submucosal dissection-induced ulcers in both groups. PPI: Proton-pump inhibitor; RM: Rebamipide.

Figure 5 Proportion of patients who developed a flat scar after ulcer healing in both groups. PPI: Proton-pump inhibitor; RM: Rebamipide.

Figure 6 At 8 wk, granulation lesions following ulcer healing in the proton-pump inhibitors treated group.